Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment Po-Lan Su (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing), Jeng-Shiuan Tsai (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing), Szu-Chun Yang (Data curation) (Writing -review and editing), Yi-Lin Wu (Data curation) (Writingreview and editing), Yau-Lin Tseng (Data curation) (Writing -review and editing), Chao-Chun Chang (Data curation) (Writing -review and editing), Yi-Ting Yen (Data curation) (Writing -review and editing), Chia-Ying Lin (Data curation) (Writing -review and editing), Chien-Chung Lin (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing), Chin-Chou Wang (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing), Meng-Chih Lin (Data curation) (Writing -review and editing), Wu-Chou Su (Conceptualization) (Data curation) (Investigation) (Methodology) (Writing -review and editing)